Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECG Effects of TA-8995 in Healthy Subjects
NCT02241759Phase 1Completed
- Sponsor
- Xention Ltd.
- Start
- Aug 2014
- Primary completion
- Nov 2014
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of obicetrapib in dyslipidemia (3 arms), sponsored by Xention Ltd. Primary endpoint: Change from baseline in QT interval corrected for heart rate (QTc) for TA-8995 versus placebo at 4 days. Started Aug 2014; status: completed.
02
Drugs
obicetrapib
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02241759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02241759.